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Abstract
A conformationally restricted analog of a selective cyclopropane-bearing serotonin 2C agonist was 
designed and synthesized. A 2,2-dimethyl-2,3-dihydrobenzofuran scaffold was investigated as a 
constrained variant of a biologically active isopropyl phenyl ether. Construction of the required 
dimethyl-2,3-dihydrobenzofuran intermediate began using a procedure that relied on a microwave-
assisted alkylation reaction. The synthesis of the designed compound as its HCl salt is reported in 
a total of 12 steps and 17% overall yield. Biological evaluation revealed the constrained analog to 
be a selective serotonin 2C agonist with modest potency.
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Introduction
The serotonin 2C (5-HT2C) receptor has been found to represent a promising drug target in 
the search for new treatments for a variety of disorders, including obesity and various mental 
diseases, such as schizophrenia, depression, and anxiety.1,2,3 One of the many advantages of 
the 5-HT2C receptor as a central nervous system (CNS) drug target stems from the fact that 
it is almost exclusively found in the CNS,4,5 and thus compounds that selectively activate 
this receptor should have limited impact on peripheral tissues. However, the activation of 
two other closely related 5-HT2 receptor subtypes, namely the 5-HT2A and 5-HT2B 
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receptors, has been reported to be associated with hallucinatory effects and life threatening 
cardiac valvulopathy, respectively.6,7,8 Therefore, the identification of ligands possessing 
exquisite selectivity for the 5-HT2C versus the 5-HT2A and 5-HT2B receptor subtypes is a 
key requirement for therapeutic advancement of 5-HT2C agonists.3 However, the 
achievement of such selectivity has proven to be challenging because of the high amino acid 
sequence homology shared by members of the 5-HT2 subfamily.
During our studies aimed at designing selective 5-HT2C agonists for possible use in CNS 
diseases, compound (+)-1 was found to be a relatively potent and selective 5-HT2C agonist 
(5-HT2C: EC50 = 71 nM, Emax = 100% (of 5-HT); 5-HT2B: EC50 = 682 nM, Emax = 57%; 5-
HT2A: EC50 = 7190 nM, Emax = 17%). Based on the sum total of the structure activity 
relationship (SAR) data we had assembled for this lead candidate, we considered the 
possibility of exploring the activity of a dimethyl-2,3-dihydrobenzofuran analog 2, which 
represents a conformationally constrained version of the isopropyl phenyl ether 1. 
Conformational restriction is, of course, a well-recognized medicinal chemistry strategy for 
enhancing the binding affinity as well as the target selectivity of small molecules.9 This 
particular structure was also of interest as the heterocyclic benzofuran system is present in a 
number of drugs.10,11 For example, the 2,2-dimethyl-2,3-dihydrobenzofuran scaffold is 
found in the drug zatosetron (3),12 which is a 5-HT3 antagonist that is able to induce 
antinausea effects without affecting gastrointestinal motility.13 Zatosetron was also found to 
be an effective anxiolytic in both animal studies and human trials.14 The similarity of 
compound 2 with 3, and the fact that both compounds 1 and 3 act through serotonin 
receptors thus encouraged us to synthesize compound 2 for biological evaluation.
Result and discussion
The retro-synthetic analysis of compound (±)-2 is outlined in Figure 2. Benzaldehyde 4 was 
selected as a key intermediate, as the cyclopropylmethylamine side chain of 2 can be 
installed from this aldehyde, using methods similar to those that we have reported 
previously.15 This benzaldehyde could in turn be prepared from its corresponding benzoate 
5.16, 17 As compound 5 has previously served as an intermediate in the synthesis of 
zatosetron (3), a synthetic approach to this intermediate starting from methyl 5-chloro-2-
hydroxybenzoate (6) has been reported.12,18 We note that no spectroscopic data have been 
reported previously for the intermediates prepared in the synthesis of 5, and that this 
compound had previously been obtained in only very low yield.
The synthesis of intermediate 5 is depicted in Scheme 1. The alkylation of the starting 
material methyl 5-chloro-2-hydroxybenzoate (6) was accomplished using 3-chloro-2-
methylprop-1-ene under reflux conditions in acetone, however, this led to only a 29% yield 
of product 7.12 In order to improve the yield of this alkylation reaction, 3-bromo-2-
methylprop-1-ene was used as the alkylating reagent and the reaction was carried out under 
microwave conditions (80 °C). This method gave an improved yield (81%) of the product 7, 
and the reaction time was reduced from overnight to 1.5 h. The Claisen rearrangement of 
intermediate 7 turned out to be sluggish. Heating of 7 in NMP at 200 °C for 8 h provided a 
65% yield of product 8, with a 24% recovery of the starting material. The subsequent 
cyclization of compound 8 was brought about by refluxing in 95% formic acid, which gave 
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an excellent yield of intermediate 5. With the assistance of microwave conditions, 
intermediate 5 was prepared in 52% yield from 6 in three steps, compared to an overall 20% 
yield as reported previously.12
The ester 5 was then subjected to a sequence of lithium aluminum reduction and pyridinium 
dichromate (PDC) oxidation to give the benzaldehyde 4 in good yield. Wittig reaction of 4 
with a commercially available reagent N-methoxy-N-
methyl(triphenylphosphoranylidene)acetamide in dichloromethane at room temperature 
provided the Weinreb amide 10 in high yield. The double bond was obtained in solely the E 
form, without the observation of its Z isomer. The coupling constant of the two protons 
attached to the double bond is 16.0 Hz, which is consistent with the data reported for similar 
compounds.15 Subsequent Corey-Chaykovsky cyclopropanation of the E double bond, with 
the sulfur ylide which was generated from trimethylsulfoxonium iodide upon treatment with 
sodium hydride, gave the cyclopropane 11 as its trans isomer. The Weinreb amide was then 
reduced with diisobutylaluminium hydride at low temperature to give aldehyde 12, which 
was subsequently reduced to the corresponding alcohol 13 in excellent yield using sodium 
borohydride. The primary amine 2 was prepared from its alcohol 13 through a sequence of 
steps involving a Mitsunobu reaction employing phthalimide to afford the Gabriel imide 14, 
followed by de-protection with hydrazine. Finally, the hydrochloride salt of 2 was prepared 
using HCl in diethyl ether. This sequence of transformations provided the target compound 
in 9 steps from 5, with an overall yield of 33%. While preparative chiral HPLC methods 
were investigated for the separation of the optically pure enantiomers of the racemic Boc 
derivative of compound (±)-2, no separation was observed using either OD or OJ columns 
employing various solvent systems. Therefore, the biology activity of compound 2 was 
evaluated using its racemate.
Functional activity at the 5-HT2A, 5-HT2B and 5-HT2C receptors was determined using the 
calcium flux assay (for details of the assay, see supplementary data) for the racemic form of 
compound 2. Moderate potency was observed for compound 2 at the 5-HT2C receptors 
(EC50 = 600 nM) where it acts as a partial agonist (Emax = 66% of 5-HT). No activity was 
observed at either the 5-HT2A or 5-HT2B receptors. The absence of any 5-HT2B activity for 
compound 2 is beneficial, as this would preclude any undesirable cardiac toxicity as noted 
above. The decreased activity of this compound at 5-HT2C receptors may be a result of its 
increased steric size compared to compound 1, as previous SAR studies have shown that 
increasing the length of the ether chain by one carbon led to a significant decrease in 5-
HT2C activity.15
Conclusion
In this letter we report the design and synthesis of a selective 5-HT2C agonist compound 2 
bearing a dimethyl-2,3-dihydrobenzofuran moiety. An improved synthesis of the 
dimethyl-2,3-dihydrobenzofuran scaffold is reported that makes use of a microwave-assisted 
alkylation reaction followed by a Claisen rearrangement and a formic acid promoted 
cyclization. The 2-phenylcyclopropylmethylamine side chain of the target compound was 
synthesized using a sequence of steps involving a Wittig reaction, Corey-Chaykovsky 
cyclopropanation, reduction of a Weinreb amide, and a Mitsunobu reaction followed by 
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deprotection of the thus formed Gabriel imide. The HCl salt of the target compound was 
prepared in 12 steps in an overall yield of 17%. The functional activity of this compound at 
the 5-HT2C, 5-HT2A and 5-HT2B receptors was then determined using a calcium flux assay, 
and compound 2 was found to be a selective 5-HT2C partial agonist of moderate potency. 
The design of other analogs of 2 would thus appear to be valuable to explore.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of compounds (+)-1, (±)-2 and zatosetron (3).
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Retrosynthetic approach of compound (±)-2.
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Synthesis of benzaldehyde 5. Reagents and conditions: (a) 3-bromo-2-methylprop-1-ene, 
K2CO3, DMF, microwave, 80 °C, 1.5h, 81%; (b) NMP, 200 °C, 8h, 65%; (c) formic acid 
(95%), reflux, 3h, 98%.
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Synthesis of target compound 2. (a) LiAlH4, THF, 0 °C to rt, 2h, 92%; (b) PDC, CH2Cl2, rt, 
2h, 65%; (c) Ph3P=CHC(O)N(OMe)Me, CH2Cl2, rt, overnight, 92%; (d) Me3S+(O)I−, NaH, 
DMSO, rt, overnight, 98%; (e) DIBAL-H, THF, −78 °C to rt, 95%; (f) NaBH4, MeOH, 0 °C 
to rt, 96%; (g) Phthalimide, PPh3, DEAD, THF, rt, 85%; (h) N2H4–H2O, EtOH, reflux, 3h, 
97%; (i) 2M HCl in Et2O, rt, 2h, 81%.
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Table 1
Pharmacological profiles of compound (+)-1 and (±)-2.a
Compound
EC50, nM (Emax; % 5-HT)
5-HT2C 5-HT2B 5-HT2A
5-HT 0.20 (100%) 1.3 (100%) 2.1 (100%)
(+)-1 (TFA salt) 71 (100%) 682 (57%) 7190 (17%)
(±)-2 (HCl salt) 600 (66%) NA NA
a
Functional data was acquired with recombinantly expressed human serotonin receptors in HEK-293 (5-HT2A and 5-HT2B) and PO1C (5-HT2C) 
cell lines, fluorescence imaging plate reader (FLIPR) assay; “NA”, no activity at 10 µM.
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